Global Markets Direct’s, 'Wrinkles - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Wrinkles, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Wrinkles. Wrinkles - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
- A snapshot of the global therapeutic scenario for Wrinkles. - A review of the Wrinkles products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Wrinkles pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products.
Reasons to buy
- Identify and understand important and diverse types of therapeutics under development for Wrinkles. - Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. - Plan mergers and acquisitions effectively by identifying players of the most promising pipeline. - Devise corrective measures for pipeline projects by understanding Wrinkles pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Table Of Contents
Wrinkles - Pipeline Review, H1 2013 Table of Contents
Table of Contents 2 List of Tables 4 List of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 Wrinkles Overview 6 Therapeutics Development 7 An Overview of Pipeline Products for Wrinkles 7 Wrinkles Therapeutics under Development by Companies 9 Late Stage Products 10 Comparative Analysis 10 Mid Clinical Stage Products 11 Comparative Analysis 11 Early Clinical Stage Products 12 Comparative Analysis 12 Discovery and Pre-Clinical Stage Products 13 Comparative Analysis 13 Wrinkles Therapeutics - Products under Development by Companies 14 Companies Involved in Wrinkles Therapeutics Development 15 Allergan, Inc. 15 Merz GmbH and Co. KGaA 16 Revance Therapeutics, Inc. 17 NovaLead Pharma Pvt. Ltd. 18 Novocell, Inc. 19 Wrinkles - Therapeutics Assessment 20 Assessment by Monotherapy Products 20 Assessment by Route of Administration 21 Assessment by Molecule Type 23 Drug Profiles 25 onabotulinumtoxinA - Drug Profile 25 Product Description 25 Mechanism of Action 25 RandD Progress 25 onabotulinumtoxinA - Drug Profile 27 Product Description 27 Mechanism of Action 27 RandD Progress 27 NLP-02 - Drug Profile 29 Product Description 29 Mechanism of Action 29 RandD Progress 29 onabotulinumtoxinA - Drug Profile 30 Product Description 30 Mechanism of Action 30 RandD Progress 30 FibroStem - Drug Profile 31 Product Description 31 Mechanism of Action 31 RandD Progress 31 Autologous Human Platelet Lysate - Drug Profile 32 Product Description 32 Mechanism of Action 32 RandD Progress 32 RT-002 - Drug Profile 33 Product Description 33 Mechanism of Action 33 RandD Progress 33 Laminin Peptide YIGSR - Drug Profile 34 Product Description 34 Mechanism of Action 34 RandD Progress 34 Wrinkles Therapeutics - Drug Profile Updates 35 Wrinkles Therapeutics - Discontinued Products 39 Wrinkles - Product Development Milestones 40 Featured News and Press Releases 40 Apr 17, 2012: Fibrocell Science Announces Publication Of LAVIV Pivotal Trial Data In Dermatologic Surgery 40 Apr 17, 2012: Merz Pharma Canada Announces Health Canada Approval Of XEOMIN COSMETIC 41 Mar 14, 2012: Merz Aesthetics And Merz Pharma Commit To Full Remediation Compliance In Allergan Lawsuit 41 Nov 07, 2011: Studies Show LAVIV Effectively Improves Appearance Of Smile Line Wrinkles 42 Oct 11, 2011: Medicis Receives FDA Approval For Lip Indication For Restylane 43 Oct 03, 2011: Fibrocell Science Announces Launch Of LAVIV 44 Jun 22, 2011: Fibrocell Receives FDA Approval For Azficel-T 45 Apr 27, 2011: FDA Panel Recommends Lip Indication for Medicis's RESTYLANE 45 Mar 10, 2011: Fibrocell Science Submits Final Data From Histology Study Of Azficel-T To FDA 46 Jan 12, 2011: Fibrocell Science Receives FDA Acceptance For Review Of Azficel-T Complete Response Submission 47 Appendix 48 Methodology 48 Coverage 48 Secondary Research 48 Primary Research 48 Expert Panel Validation 48 Contact Us 49 Disclaimer 49
List of Tables
Number of Products Under Development for Wrinkles, H1 2013 7 Products under Development for Wrinkles - Comparative Analysis, H1 2013 8 Number of Products under Development by Companies, H1 2013 9 Comparative Analysis by Late Stage Development, H1 2013 10 Comparative Analysis by Mid Clinical Stage Development, H1 2013 11 Comparative Analysis by Early Clinical Stage Development, H1 2013 12 Comparative Analysis by Discovery and Pre-Clinical Stage Development, H1 2013 13 Products under Development by Companies, H1 2013 14 Allergan, Inc., H1 2013 15 Merz GmbH and Co. KGaA, H1 2013 16 Revance Therapeutics, Inc., H1 2013 17 NovaLead Pharma Pvt. Ltd., H1 2013 18 Novocell, Inc., H1 2013 19 Assessment by Monotherapy Products, H1 2013 20 Assessment by Stage and Route of Administration, H1 2013 22 Assessment by Stage and Molecule Type, H1 2013 24 Wrinkles Therapeutics - Drug Profile Updates 35 Wrinkles Therapeutics - Discontinued Products 39
List of Figures
Number of Products under Development for Wrinkles, H1 2013 7 Products under Development for Wrinkles - Comparative Analysis, H1 2013 8 Products under Development by Companies, H1 2013 9 Late Stage Products, H1 2013 10 Mid Clinical Stage Products, H1 2013 11 Early Clinical Stage Products, H1 2013 12 Discovery and Pre-Clinical Stage Products, H1 2013 13 Assessment by Monotherapy Products, H1 2013 20 Assessment by Route of Administration, H1 2013 21 Assessment by Stage and Route of Administration, H1 2013 22 Assessment by Molecule Type, H1 2013 23 Assessment by Stage and Molecule Type, H1 2013 24